Previous 10 | Next 10 |
Truist analyst Gregg Gilbert has cut shares of Evolus, Inc. (EOLS) from buy to hold.He writes that with the Evolus' recent IP settlement with Abbvie (ABBV) and Medytox over Jeuveau, the company's stock is readjusting to a more fair value.However, he says he is still "bullish on managemen...
NEWPORT BEACH, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS) today announced its preliminary, unaudited, net revenues for the fourth quarter and full year ended December 31, 2020. The preliminary unaudited results described in this press release are estimates only an...
Otonomy (OTIC) -51% after Otividex fails late-stage Ménière’s disease study.Ebix (EBIX) -32% as auditor resigns after flagging material weakness.Energous (WATT) -20%.MoneyGram International (MGI) -17% on Q4 earnings.Petroleo Brasileiro S.A. - Petrobra...
Gainers: [[RNWK]] +14.1%. [[VIOT]] +8%. [[IMUX]] +7.5%. [[CRVS]] +6.4%. [[OTIC]] +4.4%.Losers: [[PT]] -4.7%. [[OBSV]] -2.8%. [[PETS]] -2.6%. [[EVGN]] -2%. [[EOLS]] -1.7%. For further details see: PETS, IMUX, EVGN and OTIC among after-hours movers
We propose a method for selling options that defies many myths around options selling. We analyzed options prices using statistical modelling and calculus to improve the "expected value" of trading versus conventional principles. Trades based on the criteria below are likely to wi...
NEWPORT BEACH, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 10 th Annual SVB Leeri...
Gainers: Vaccinex (VCNX) +106%.Evolus (EOLS) +75%.Energous (WATT) +45%.Viomi Technology (VIOT) +44%.Casa Systems (CASA) +42%.Canaan (CAN) +40%.JMP Group (JMP) +39%.Renren (RENN) +37%.The9 (NCTY) +32%.Forest Road Acquisition (FRX) +26%.Losers: China SXT Pharmaceuticals (SXT...
AbbVie ([[ABBV]] -0.5%), Evolus ([[EOLS]]), and Medytox have agreed to settle the dispute over intellectual property rights for Jeuveau. Trading of Evolus share is on hold and expected to resume at 9:50 AM EST.Under the agreements, the companies will fully resolve all outstanding litigation r...
AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation PR Newswire NORTH CHICAGO, Ill. and NEWPORT BEACH, Calif. and SEOUL , Feb. 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce s...
Today, we take our first in-depth look at a medical cosmetology company named Evolus. The company's rollout of Botox competitor Jeuveau has been hampered by impacts from the pandemic as well as litigation. A full investment analysis follows in the paragraphs below. For furth...
News, Short Squeeze, Breakout and More Instantly...
Total Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023 Raises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million, Representing Year-Over-Year Growth of 34% at the Top End Improved Quarterly GAAP Operating Loss to $7.7 Million; Delivered First Ever Qua...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host an Investor Day on Thursday, September 12, 2024 in New York City. Attendees can join in-person or participate via webcast. The even...
Launching into this growth market 1 as part of the company’s geographic expansion strategy Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals Evolus, Inc. (NASDAQ: EOLS), a perf...